Abrdn Life Sciences Investors (NYSE:HQL) Sees Significant Growth in Short Interest

Abrdn Life Sciences Investors (NYSE:HQL) was the target of a significant increase in short interest in November. As of November 15th, there was short interest totalling 74,100 shares, an increase of 17.2% from the October 31st total of 63,200 shares. Based on an average daily trading volume, of 74,100 shares, the days-to-cover ratio is currently 1.0 days.

Abrdn Life Sciences Investors Stock Up 0.9 %

Shares of NYSE HQL traded up $0.13 on Friday, hitting $14.26. The company’s stock had a trading volume of 43,115 shares, compared to its average volume of 85,681. The stock has a 50 day moving average of $14.76 and a 200-day moving average of $14.68. Abrdn Life Sciences Investors has a 12-month low of $11.78 and a 12-month high of $15.90.

Abrdn Life Sciences Investors Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, January 10th. Shareholders of record on Thursday, November 21st will be given a dividend of $0.50 per share. This is an increase from Abrdn Life Sciences Investors’s previous quarterly dividend of $0.49. The ex-dividend date is Thursday, November 21st. This represents a $2.00 annualized dividend and a yield of 14.03%.

Hedge Funds Weigh In On Abrdn Life Sciences Investors

Institutional investors have recently made changes to their positions in the stock. Sanctuary Advisors LLC grew its holdings in shares of Abrdn Life Sciences Investors by 11.4% during the third quarter. Sanctuary Advisors LLC now owns 13,256 shares of the company’s stock worth $183,000 after buying an additional 1,355 shares in the last quarter. Needham Investment Management LLC grew its position in shares of Abrdn Life Sciences Investors by 3.2% in the third quarter. Needham Investment Management LLC now owns 352,719 shares of the company’s stock valued at $5,319,000 after purchasing an additional 10,904 shares during the period. Penserra Capital Management LLC acquired a new position in Abrdn Life Sciences Investors in the third quarter valued at $11,702,000. Kapstone Financial Advisors LLC acquired a new position in Abrdn Life Sciences Investors in the third quarter valued at $177,000. Finally, Ashton Thomas Securities LLC acquired a new stake in Abrdn Life Sciences Investors in the 3rd quarter worth about $148,000. 32.21% of the stock is owned by institutional investors and hedge funds.

Abrdn Life Sciences Investors Company Profile

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.